RECRUITING

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Fairview Hospital.

Official Title

Comparison of Efficacy of Sugammadex Versus Neostigmine in Reversing Neuromuscular Blocks in Patients Having Outpatient Endoscopic Retrograde Cholangiopancreatography (ERCP). A Randomized, Double-Blinded Trial

Quick Facts

Study Start:2024-06-01
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06136585

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * ≥18 years old
  2. * American Society of Anesthesiologist physical status 3-4
  3. * Scheduled for outpatient endoscopic retrograde cholangiopancreatography
  1. * Difficult Airway
  2. * Neuromuscular Disorders (eg: ALS, Botulism, Myasthenia Gravis, Lambert-eaton syndrome)
  3. * End stage renal disease requiring dialysis
  4. * Pregnancy or breast-feeding
  5. * Allergy to Fentanyl
  6. * Allergy to Neuromuscular blocking drugs (eg: rocuronium)
  7. * Allergy to Neuromuscular reversal drugs (eg: sugammadex or neostigmine)
  8. * Allergy to glycopyrrolate

Contacts and Locations

Study Contact

Sabry Ayad, MD
CONTACT
216-476-7052
Saayad@ccf.org
Erica Linna, RN
CONTACT
216-633-5073
Linnae@ccf.org

Principal Investigator

Ryu Komatsu, MD
PRINCIPAL_INVESTIGATOR
The Cleveland Clinic

Study Locations (Sites)

Cleveland Clinic Fairview Hospital
Cleveland, Ohio, 44111
United States

Collaborators and Investigators

Sponsor: The Cleveland Clinic

  • Ryu Komatsu, MD, PRINCIPAL_INVESTIGATOR, The Cleveland Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-01
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2024-06-01
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Neuromuscular Blocks